2016 results from seven companies expected next week

BioPharmaDive has provided an interesting report of what we can expect from the pharma and biotech companies which will report their results next week. Such remarks are significant, especially following declarations by the US President-elect. As for Johnson & Johnson, little news is expected on the deal with Actelion, although the US-based giant has confirmed exclusive talks with the Swiss biotech. The fourth quarter results will be discussed on January 24th, probably focusing on Remicade, which could be soon impacted by its biosimilar Inflectra, while growth from Xarelto and Imbruvica could keep boosting the group’s growth. Results from two major groups—Novartis and Vertex, are expected the following day, January 25th. The Swiss giant took an upturn in Q4, yet sales throughout 2016 were lower than in 2015. The company relies on Gilenya, Cosentyx and Entresto. The last of the three, after a slow start ,appears to be on the right track. Novartis is likely to outline its strategy to boost growth, despite the poor performance by its eye care business and the patent loss of Gleevec. Novartis’ cancer therapy CAR-T, indeed, is on the horizon and could be filed for approval early this year. Updates on the the company’s successful deal with Conatus Pharmaceuticals are expected as well. Moving on to Vertex, its leading product Orkambi had a better performance than expected, yet the company has set a modest target for it in 2017. For Kalydeco, it expects results comparable to 2016 and plans to submit a therapy combining the drug with investigational candidate tezacaftor for approval next year. Biogen, whose CEO Vounatsos will announce its results on January 26th, has already anticipated it intends to prioritize the neurological disorders area, especially multiple sclerosis, SMA and other neurodegenerative disorders. The company is expected to give updates about Spinraza and outlook for the investigational Alzheimer’s drug aducanumab. There will be interest about possible transactions, since Biogen was allegedly targeted by MSD and Allergan, which have denied the rumors. Results from BMS are expected on January 26th as well. It is known that BMS’ immuno-oncology business is under the spotlight. Specifically, now that MSD’s Keytruda has been approved in first-line lung cancer, BMS could be concerned for Opdivo, although it has been approved for use in a broader patient population and for more indications than its competitor. Celgene, which has concluded several deals during Q4, is expected to report its results on the same day, in addition to further details and an interesting outlook. The company is currently relying on a pivotal drug for its business, that is Revlimid. Abraxane, instead, is facing severe competition from the immuno-oncology field. Finally, AbbVie’s results, which are attracting interest from analysts, are awaited on 27th January. Still, investors seem slightly skeptical about Humira still playing a crucial role for the company’s results, since its biosimilars are starting approaching the US market. However, relevant development is expected by new AbbVie products, including Rova-T, likely to deliver multi-billion figures once it is launched on the market in 2018. (Source BioPharmaDIVE)